logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kazuki Sudo

national cancer center - japan
H指数:29
被引数:3,004

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial

原发肿瘤切除可降低新诊断IV期乳腺癌的主要局部并发症风险：来自JCOG1017随机对照试验的二次数据分析

bjs
IF0
2026-05-010
PRE
Makoto Ishitobi; Kiyo Tanaka; Akihiko Shimomura; Takashi Yamanaka; Takahiro Tsukioki; Hiroji Iwata; Fumikata Hara; Tomomi Fujisawa; Keita Sasaki; Riku Kajikawa; Takehiko Sakai; Yasuaki Sagara; Hideo Shigematsu; Yukinori Ozaki; Kazuki Nozawa; Kazuki Sudo; Yoichi Naito; Kaori Terata; Toshiyuki Ishiba; Haruhiko Fukuda; Tadahiko Shien
MTAP loss in advanced mucinous ovarian carcinoma: Prevalence, co-alteration patterns, and prognostic association in a nationwide Japanese genomic registry

MTAP缺失在晚期黏液性卵巢癌中的流行率、共突变模式和预后关联：一项基于日本全国基因组登记研究

Gynecologic Oncology
IF4.1
2026-04-230
PRE
Taro Yamanaka; Yuki Kojima; Jun Sato; Hiroki Tamura; Yutaka Natori; Takuro Saiki; Mai Hoshino; Ayumi Saito; Shosuke Kita; Aiko Maejima; Tatsunori Shimoi; Kazuki Sudo; Takafumi Koyama; Kan Yonemori
Biomarker analysis of cadherin 6 and folate receptor alpha (FRα) expression, and raludotatug deruxtecan (R-DXd) antitumor activity by FRα status, in patients with platinum-resistant ovarian cancer from REJOICE-Ovarian01 and a first-in-human Phase 1 study of R-DXd

在REJOICE-Ovarian01研究和R-DXd首次人体I期研究中，对铂耐药卵巢癌患者中钙黏蛋白6及叶酸受体α（FRα）表达与FRα状态相关的拉鲁多塔妥德鲁克特坎（R-DXd）抗肿瘤活性的生物标志物分析

Gynecologic Oncology
IF4.1
2026-04-230
PRE
Kathleen Moore; Isabelle Ray-Coquard; Erika Hamilton; Kosei Hasegawa; Debra Richardson; Alexander Philipovskiy; Kazuki Sudo; Jung-Yun Lee; Nicoletta Colombo; David Garcia-Illescas; Sany Hoxha; Madan Kundu; Yusuke Myobatake; Connor Mailley; Sandra Re; Tsuyoshi Hirata; Cynthia Turcotte; Weiguo Feng; Nanae Izumi
Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid Tumor

早期霉酚酸酯联合疗法作为实体瘤患者免疫检查点抑制剂诱导的免疫相关肝炎的有效治疗方法

Cancer Medicine
IF3.1
2026-03-190
OAAI
Igawa, Yukiko Shimoda; Yoshida, Tatsuya; Sato, Jun; Yoshinami, Yuri; Hibino, Yukiko; Arima, Takamichi; Maruki, Yuta; Shoji, Hirokazu; Namikawa, Kenjiro; Sudo, Kazuki; Honma, Yoshitaka; Okita, Natsuko; Hashimoto, Hironobu; Yamazaki, Naoya; Okusaka, Takuji; Yonemori, Kan; Yamamoto, Noboru; Ohe, Yuichiro; Kato, Ken
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer

POLH和RAD51基因的种系变异是激素受体阴性年轻发病乳腺癌风险的候选变异。

npj Breast Cancer
IF7.6
2025-11-280
OAAI
Shu Yazaki; Rui Kitadai; Yukihide Momozawa; Teruhiko Yoshida; Takashi Yamanaka; Sho Shiino; Chisako Yamauchi; Kenichi Harano; Motonobu Saito; Yosuke Hirotsu; Hisaki Aiba; Ryuji Hamamoto; Chikako Shimizu; Akihiko Shimomura; Tatsunori Shimoi; Kazuki Sudo; Masayuki Yoshida; Kuniko Sunami; Yuichi Shiraishi; Aya Kuchiba; Megumi Hori; Kota Katanoda; Sadaaki Takata; Ayumi Ogawa; Masahiro Torasawa; Akifumi Mochizuki; Yoko Shimada; Kengo Hiranuma; Erisa Fujii; Makoto Hirata; Yuji Yamashita; Takahiro Kogawa; Takeshi Murata; Saori Fujiwara; Yohei Miyagi; Hiroshi Nakagomi; Kazunoshin Tachibana; Koichi Matsuda; Yoshinori Murakami; Katsushi Tokunaga; Yosuke Kawai; Biobank Japan Project; Masao Omata; Tohru Ohtake; Akihiko Suto; Tatsuya Onishi; Yoichi Naito; Toshinari Yamashita; Kan Yonemori; Takashi Kohno; Kouya Shiraishi
RESULTS OF A MULTICENTER PHASE 2 BASKET TRIAL EVALUATING THE EFFICACY OF TASURGRATINIB (E7090) IN PATIENTS WITH ADVANCED SOLID TUMORS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) GENE ALTERATION, INCLUDING THOSE WITH PRIMARY BRAIN TUMORS: FORTUNE STUDY

评估TASURGRATINIB（E7090）在具有成纤维细胞生长因子受体（FGFR）基因变异的晚期实体瘤患者（包括原发性脑肿瘤患者）中的疗效的多中心II期篮式试验结果：FORTUNE研究

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Takahashi, Masamichi; Sudo, Kazuki; Matsubara, Junichi; Tsuchihashi, Kenji; Kinoshita, Ichiro; Takahashi, Masanobu; Chiba, Yohei; Kohsaka, Shinji; Sadachi, Ryo; Machida, Ryunosuke; Ichimura, Masahiko; Okuma, Hitomi Sumiyoshi; Anjo, Kenta; Kurishita, Kazumi; Nakamura, Kenichi; Yonemori, Kan
Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer

monarchE试验中高风险HR阳性、HER2阴性乳腺癌队列1的基线风险变异性与纳入标准的关系

Breast Cancer
IF2.9
2025-07-280
OA
Mai Hoshino; Tatsunori Shimoi; Taro Yamanaka; Rui Kitadai; Munehiro Ito; Ayumi Saito; Shosuke Kita; Asuka Kawachi; Hitomi Sumiyoshi Okuma; Aiko Maejima; Yuki Kojima; Kazuki Sudo; Emi Noguchi; Yasuhiro Fujiwara; Jun Kato; Kan Yonemori
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)

AZD5335的一期人体研究结果，该药物是一种叶酸受体α（FRa）靶向抗体药物偶联物，用于治疗对铂类耐药的复发性卵巢癌（PRROC）患者（pts）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Shapira-Frommer, R.; Sudo, K.; Harano, K.; Mileshkin, L.; Perets, R.; Song, M.; Cohen, J.; Huang, Y-F.; Ambrose, H.; Brier, T.; Dosani, A.; Fraenkel, P. G.; Kmieciak, A.; Mitchell, P.; Myers, C.; Wang, J.; Odegbami, R. I.; Sykes, A.; Turner, S.; Meric-Bernstam, F.
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
NPJ BREAST CANCER
IF7.6
2024-08-220
OA
Noguchi, Emi; Yamanaka, Takashi; Mukai, Hirofumi; Yamamoto, Naohito; Chung, Chi-Feng; Lu, Yen-Shen; Chang, Dwan-Ying; Sohn, Joohyuk; Kim, Gun Min; Lee, Kyung-Hun; Lee, Soo-Chin; Iwasa, Tsutomu; Iwata, Hiroji; Watanabe, Kenichi; Jung, Kyung Hae; Tanabe, Yuko; Kang, Seok Yun; Yasojima, Hiroyuki; Aogi, Kenjiro; Tokunaga, Eriko; Sim, Sung Hoon; Yap, Yoon Sim; Matsumoto, Koji; Tseng, Ling-Ming; Umeyama, Yoshiko; Sudo, Kazuki; Kojima, Yuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Nakamura, Kenichi; Fujiwara, Yasuhiro; Tamura, Kenji; Yonemori, Kan
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine

eribulin或卡培他滨治疗HER2-null和HER2-low晚期乳腺癌的临床病理和预后特征

BREAST CANCER
IF2.9
2024-08-142
OAAI
Kitadai, Rui; Shimoi, Tatsunori; Yazaki, Shu; Okuma, Hitomi Sumiyoshi; Hoshino, Mai; Ito, Munehiro; Saito, Ayumi; Kita, Shosuke; Kojima, Yuki; Nishikawa, Tadaaki; Sudo, Kazuki; Noguchi, Emi; Fujiwara, Yasuhiro; Yoshida, Masayuki; Yonemori, Kan
Clonal Architecture of circulating tumor DNA predicts Early Progression on Tamoxifen With or Without Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer: NCCH1607/PATHWAY trial
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Yap, Yoon-Sim; Kojima, Yuki; Hamada, Akinobu; Mukai, Hirofumi; Lu, Yen-Shen; Sohn, Joo Hyuk; Umeyama, Yoshiko; Noguchi, Emi; Sudo, Kazuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Yagishita, Shigehiro; Yoshida, Masayuki; Kohsaka, Shinji; Shiraishi, Kouya; Nakamura, Kenichi; Tamura, Kenji; Yonemori, Kan
Genomic landscape of circulating tumor DNA in cervical cancer in Asia: NCCH1905/A-TRAIN trial
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Yehgambaram, Prathepamalar; Kojima, Yuki; Sudo, Kazuki; Yazaki, Shu; Tokura, Momoko; Ito, Munehiro; Hoshino, Mai; Fui, Wong Yoke; Voon, Pei Jye; Tan, David S. P.; Lertkhachonsuk, Arb-aroon; Anh Tuan Pham; Thinh Dang Huy Quoc; Ishak, Wan Zamaniah Wan; Yoshida, Hiroshi; Kohsaka, Shinji; Nagasaka, Yukari; Machida, Ryunosuke; Hata, Tomomi; Nakamura, Kenichi; Yonemori, Kan

研究方向

暂未获取到该数据
K
Kan Yonemori
H 指数:48论文数:1,048被引数:1.0万
T
Tatsunori Shimoi
H 指数:21论文数:357被引数:2,456
Y
Yuki Kojima
H 指数:20论文数:349被引数:1,485
E
Emi Noguchi
H 指数:17论文数:133被引数:1,073
H
Hitomi Sumiyoshi Okuma
H 指数:14论文数:260被引数:569
T
Tadaaki Nishikawa
H 指数:17论文数:174被引数:1,746
Y
Yasuhiro Fujiwara
H 指数:65论文数:973被引数:1.7万
A
Ayumi Saito
H 指数:14论文数:94被引数:531
J
Jaffer A. Ajani
H 指数:152论文数:1,740被引数:12.2万
M
Maki Tanioka
H 指数:22论文数:179被引数:1,676